Supporting information

The file contains a table with statistical analyses showing effects of analysed risk factors on survival endpoints, it also contains a schematic depiction of the trial treatment for better illustration and a graph showing the timing of occurrence of dose limiting toxicities, showing the early dominance of non-hematologic toxicities.

Supplementary table

Table S1.

| Gene mutations          | Exp(B) | 95% CI    | p value* | Exp(B) | 95% CI    | p value* |
|-------------------------|--------|-----------|----------|--------|-----------|----------|
| ATM (yes vs no)         | 1·86   | 0·80-4·34 | 0·14     | 0·80   | 0·21-2·99 | 0·74     |
| BIRC3 (yes vs no)       | 2·43   | 0·56-10·54| 0·22     | 2·52   | 0·31-20·42| 0·37     |
| NFKBIE (yes vs no)      | 1·31   | 0·39-4·43 | 0·66     | 2·84   | 0·71-11·35| 0·12     |
| NOTCH1 (yes vs no)      | 2·03   | 0·88-4·72 | 0·092    | 3·75   | 1·00-14·02| 0·035    |
| SF3B1 (yes vs no)       | 0·41   | 0·06-3·05 | 0·37     | 0·97   | 0·12-7·80 | 0·98     |
| TP53 (yes vs no)        | 2·39   | 0·55-10·32| 0·23     | 13·55  | 2·40-76·63| <0·0001  |
| ZNF292 (yes vs no)      | 1·10   | 0·33-3·74 | 0·87     | 1·91   | 0·39-9·29 | 0·42     |
| FISH cytogenetics (high risk vs low risk)** | 2·33   | 1·03-5·26 | 0·037    | 1·94   | 0·25-7·30 | 0·32     |
| IgVH (unmutated vs mutated) | 3·90   | 1·41-10·80| 0·005    | 5·27   | 0·64-43·13| 0·084    |
| ≥2 mutations (yes vs no) | 3·35   | 1·00-0·07 | 0·051    | 4·06   | 1·01-16·26| 0·032    |
| MRD neg after induction (yes vs no) | 0·33   | 0·14-0·77 | 0·007    | 0·53   | 0·12-2·39 | 0·40     |

*(Log Rank (Mantel-Cox))

** high risk defined by presence of del 17p and/or del11q, low risk defined as non-high risk

Supplementary figures
**Figure S1.** Trial design.

**Figure S2.** Occurrence of first dose limiting toxicity (DLT) per patient, as assessed at the end of treatment cycle (induction).